Peptide education

CJC-1295 no DAC

Modified GRF · Modified GRF 1-29 · Mod GRF · Mod GRF 1-29 · CJC-1295 without DAC

CJC-1295 no DAC is the short-acting half of the CJC-1295 name: the same tetrasubstituted GHRH(1-29) backbone sold as Modified GRF 1-29 or Mod GRF, minus the albumin-binding add-on that makes the DAC version last a week. Its half-life is about 30 minutes, which is why community protocols inject it one to three times a day instead of weekly. The uncomfortable part is where its data comes from: the well-known CJC-1295 human studies used the DAC form, so direct modern human evidence for the no-DAC products people actually buy is close to absent. What fills the gap is GHRH logic, borrowed DAC data, and market convention.

CJC-1295 no DAC has the thinnest evidence base of any name in this family: the human studies everyone cites belong to its long-acting DAC sibling. For the vials actually sold online, the honest first question is not whether it works but what it is.

By the Peptides Media Editorial Team Editorial policy8 min read

Key takeawayConfirm the exact CJC form

Common routeSubcutaneous in market use

Direct human dataVery limited

Main confusionDAC vs no-DAC

Overview

Quick answer

No-DAC CJC-1295 is not CJC-1295 DAC, an ipamorelin blend, tesamorelin, or ordinary sermorelin. FDA materials describe multiple CJC-1295-related substances with overlapping names, and that naming confusion matters because dose schedules, exposure time, safety signals, and product-quality claims can change when the actual molecule changes.

What is CJC-1295 no DAC?

A marketed name for the non-DAC version of CJC-1295, generally the same molecule as Modified GRF 1-29: a stabilized GHRH fragment that prompts the pituitary to release GH in short pulses. The no-DAC label means it lacks the albumin-binding extension that stretches the DAC form's action to about a week.

What do people use or discuss it for?

GH pulses for fat loss, lean mass, sleep, recovery, and anti-aging, almost always paired with ipamorelin to combine GHRH and ghrelin-receptor signaling. Those are clinic, forum, and vendor themes; none of them is an outcome measured in a controlled no-DAC study.

What route, amount, and schedule details are documented?

No labeled or validated no-DAC regimen exists. The market pattern is subcutaneous, roughly 100 mcg one to three times daily in community descriptions, often fasted and often matched with an equal amount of ipamorelin: convention, not tested dosing.

Why is the name so important?

Because the evidence splits on it. FDA treats DAC and non-DAC CJC-1295 as different active moieties and describes inconsistent naming across related substances, so a product or post that says only CJC-1295 may be importing the week-long DAC data into a 30-minute molecule.

What matters first?

Identity, before anything else. Separate no-DAC from DAC pharmacology, from tesamorelin's approved indication, and from blend marketing; until the molecule in the vial is established, no study or schedule can be applied to it.

Reported practice

Commonly reported protocol

CJC-1295 no DAC community-reported use

Route

Subcutaneous injection

Typical amount

Community use is usually described as 100 mcg per injection, one to three times daily, usually fasted and often paired with an equal amount of ipamorelin. Some describe 1 to 2 mg per week split across daily injections instead.

Frequency

One to three times daily in most descriptions

Duration

Most often 8 to 12 week cycles

Community Mod GRF 1-29 protocols. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail

Evidence

Evidence snapshot

Best-supported statementThe exact form has to be named

FDA materials describe multiple CJC-1295-related substances and separate DAC from non-DAC active moieties.

FDA

Direct no-DAC evidenceSparse human support

These sources help explain GHRH analogs and why identity matters, but they do not provide modern clinical outcome data for marketed no-DAC products.

FDA PMID 2866496

Related human evidenceDAC biomarkers only

Related DAC studies in healthy adults reported GH and IGF-1 increases, but those studies do not cover no-DAC fat-loss, muscle, sleep, recovery, or anti-aging outcomes.

PMID 16352683 PMID 17018654 FDA

Product-quality issueLot evidence has to cover more than purity

FDA materials discuss peptide characterization, impurity, aggregation, bioburden, endotoxin, and naming concerns for CJC-1295-related substances.

FDA

Claims

Common claims vs evidence

Claim	Human evidence	Mechanistic evidence	Anecdotal evidence	Verdict
CJC-1295 no DAC raises growth hormone and IGF-1.	The strongest human biomarker evidence comes from related CJC-1295 DAC studies, where subcutaneous dosing raised GH and IGF-1 in healthy adults. Direct evidence for marketed no-DAC products is still weaker.	The idea is biologically plausible because no-DAC is discussed as a GHRH analog, and older GHRH-fragment work shows that modified GHRH analogs can stimulate the GH axis.	Clinic, forum, Reddit, and vendor discussions commonly describe no-DAC as a shorter-acting pulse-oriented peptide, often paired with ipamorelin. Product identity and outcomes have to be checked separately.	Plausible endocrine mechanism, but no modern no-DAC clinical outcome result. PMID 16352683 PMID 17018654 PMID 2866496
It burns fat, builds muscle, or improves body composition.	The cited sources do not include a controlled no-DAC body-composition outcome. A related DAC HIV visceral-obesity trial was registered, but the registry entry has no completed efficacy results.	GH and IGF-1 biology explains why body-composition claims travel with GHRH analogs. Hormone-marker movement can explain the hypothesis, but it does not measure fat loss or lean mass.	Fat-loss and body-recomposition claims are common in clinic, protocol-blog, forum, Reddit, and vendor language, especially around CJC/ipamorelin combinations.	This is popular extrapolation and marketing, not a measured no-DAC result. FDA NCT00267527
It improves sleep, recovery, skin, joints, or anti-aging.	None of the cited no-DAC sources establish these outcomes in controlled human studies. The related DAC studies measured endocrine biomarkers rather than sleep quality, workout recovery, skin outcomes, joint mobility, or healthy-aging endpoints.	The GH axis is involved in metabolism, tissue remodeling, and repair, so the idea is understandable as biology-based speculation.	Online reports and clinic marketing often discuss better sleep, recovery, healing, and anti-aging, but they usually lack confirmed product identity, consistent dosing, medical follow-up, and comparison groups.	Describe these as clinic, vendor, and online claims until direct no-DAC outcome studies are available. FDA
No-DAC is simply the safer or more natural version of CJC-1295.	Long-term safety remains unmeasured for no-DAC products. FDA materials raise concerns about limited clinical data, immunogenicity, peptide characterization, impurities, aggregation, and adverse-event reports for CJC-1295-related products.	A shorter exposure profile may be one reason people prefer no-DAC, but shorter action does not automatically lower risk, especially when product identity and sterile quality are uncertain.	Forum and clinic discussions often contrast no-DAC with DAC as more pulse-like, but those comparisons are usually not tied to controlled safety data.	Shorter acting does not automatically mean safer. The safety question remains open. FDA
A CJC-1295 no-DAC vial with a COA matches the research.	No cited clinical source verifies that gray-market or research-use no-DAC vials match the materials discussed in regulatory or historical pharmacology sources.	This is a manufacturing and testing problem rather than a receptor problem: identity, salt form, concentration, impurities, aggregates, sterility, endotoxin, degradation, and storage all matter.	Vendor listings often present vial size, purity percentage, and sometimes endotoxin or weight testing. FDA materials explain why limited COA data can still miss important injectable-product risks.	Lot paperwork can start the check, but it still has to connect the vial to the right molecule, concentration, sterility, endotoxin control, and injectable-product handling. FDA

Bottom line

Main takeaway

If you just heard the name

CJC-1295 no DAC is a short-acting GH-releasing peptide whose online reputation is much larger than its own evidence. The human data behind the CJC name belongs to a different, longer-acting form.

If you are comparing products

Make the seller or the post say exactly which molecule it is: no-DAC, DAC, Modified GRF, a blend, or something borrowing the name. That single detail determines which evidence, if any, applies.

Best starting points

The sources support mechanism and identity questions, not outcomes: FDA's CJC-1295 review for naming and safety concerns, older GHRH-analog pharmacology for plausibility, and the 2006 DAC studies as adjacent context only.

Identity

What it is

CJC-1295 no DAC is a non-DAC GHRH analog: the tetrasubstituted GHRH(1-29) backbone also known in the market as Modified GRF 1-29 or Mod GRF. Without the DAC's albumin anchor it acts for roughly 30 minutes, which is the entire basis of its pulse-oriented reputation.

That reputation is the problem. The CJC-1295 studies people cite, days of elevated GH and IGF-1, belong to the DAC form, a different exposure profile by design. For marketed no-DAC products, the cited record offers no modern human pharmacokinetic file and no outcome trial of any kind.

What exists instead is borrowed plausibility. Older modified-GHRH studies from the 1980s show the analog class can stimulate the GH axis, and the DAC data show what sustained stimulation looks like in humans. Neither measures what a fasted pre-bed injection from a research-use vial does to body composition, sleep, or recovery.

The market fills that vacuum with stacks and schedules. No-DAC is sold blended with ipamorelin or dosed alongside it, listings alternate between CJC-1295 and Mod GRF naming, and salt forms are rarely stated. Every one of those variables decides which evidence could apply, which is why identity comes before effects here.

How people talk about it online

Clinic and med-spa pages frame no-DAC as the physiologic choice: shorter-acting, pulse-friendly, usually offered with ipamorelin as a GHRH-plus-secretagogue stack. More natural pulses is a plausible-sounding design argument, not a measured benefit.

Forum and Reddit threads get granular: fasted timing, pre-bed injections, water retention, tingling, headaches, hunger, and running comparisons between DAC and no-DAC. The reported routines, 100 mcg one to three times daily for 8 to 12 weeks, are community convention, and the side-effect chatter is a reminder that shorter acting is not the same as known safe.

Vendor listings complete the picture: milligram vials under CJC-1295, no-DAC, or MOD-GRF(1-29) labels, with purity percentages but no salt form, finished-product sterility, or storage history. A purity number cannot tell you which molecule, or which evidence, you are holding.

Use context

Routes, doses, and cycle patterns

There is no labeled regimen or well-characterized human dosing study for the no-DAC products people see online. The concrete numbers come from related DAC studies or older GHRH-analog work, while real-world use is mostly clinic, forum, Reddit, vendor, and gray-market discussion. DAC study dosing can explain why people talk about GH and IGF-1, but it does not convert directly to no-DAC vials.

Human studies and product labels

No approved no-DAC label

Purpose: Regulatory status and use limits
Context: FDA compounding and product-identity materials
Route: No labeled-use route
Amount: No labeled amount
Frequency: No labeled schedule
Duration: No labeled duration

FDA materials reviewed CJC-1295-related bulk substances and described naming, characterization, clinical-data, and safety concerns. That supports identity separation rather than an approved-use regimen.

FDA

Related DAC healthy-adult biomarker studies

Purpose: GH and IGF-1 pharmacology
Context: Human DAC studies used as adjacent evidence only
Route: Subcutaneous
Amount: 30, 60, 125, and 250 mcg/kg in related DAC studies
Frequency: Single dose, weekly, or biweekly in related DAC studies
Duration: Hormone follow-up over days; repeated exposure over short study windows

These schedules belong to related DAC evidence. They show why CJC-1295 is discussed as a GH/IGF-1 peptide, but they are not no-DAC dosing instructions.

PMID 16352683 PMID 17018654 FDA

Older GHRH-analog context

Purpose: Historical GH-axis pharmacology
Context: Older human GHRH and D-Ala2 GHRH analog studies
Route: Injection-based research settings
Amount: Study-specific amounts; not a modern no-DAC product regimen
Frequency: Study-specific
Duration: Short pharmacology windows

These papers help explain why modified GHRH fragments were studied, but they do not establish modern CJC-1295 no-DAC product identity, consumer dosing, or long-term outcomes.

PMID 6236914 PMID 2866496

Real-world discussion

Community Mod GRF 1-29 protocols

Purpose: Pulsatile GH release for recovery, sleep, and body composition
Context: Forums, vendor listings, and protocol blogs
Route: Subcutaneous injection
Amount: Community use is usually described as 100 mcg per injection, one to three times daily, usually fasted and often paired with an equal amount of ipamorelin. Some describe 1 to 2 mg per week split across daily injections instead.
Frequency: One to three times daily in most descriptions
Duration: Most often 8 to 12 week cycles

CJC-1295 no DAC is the same Mod GRF 1-29 molecule discussed in the human pharmacology literature, but community schedules are conventions, not tested regimens. The pairing with a secretagogue mirrors studied GHRH synergy. Reported as context, not a recommendation.

What varies

Identity: decide whether the source is discussing no-DAC, DAC, Modified GRF, tesamorelin, sermorelin, ipamorelin, or a blend before applying any claim.
Route: most online discussion assumes subcutaneous injection, which makes sterility, endotoxin, reconstitution, storage, and dose math central concerns.
Amount: DAC studies use weight-based microgram-per-kilogram schedules; vendor no-DAC products are usually sold as milligram vials, so the numbers are not directly comparable.
Frequency: no-DAC is usually discussed as shorter acting than DAC, but market timing language is not no-DAC human pharmacokinetic data.
Cycle length: clinic and forum cycle language varies, and no dependable no-DAC cycle is available.

Human data

Human evidence

For the exact no-DAC products sold today, direct human evidence is close to absent. The adjacent record does three things: FDA materials document naming, characterization, and safety concerns across CJC-1295-related substances; the 2006 DAC studies supply related biomarker data for a longer-acting form; and older GHRH-analog papers establish that the class can stimulate GH release. None of that measures fat loss, muscle gain, sleep, recovery, skin, or anti-aging outcomes for no-DAC, and none of it verifies what is in a market vial. The honest summary is that no-DAC use is an extrapolation layered on an extrapolation.

Evidence maturity

Most no-DAC claims borrow from related DAC biomarker data and GHRH logic; direct human outcome evidence for marketed no-DAC products does not exist.

GHRH-analog origins

1980s modified GHRH-fragment studies established that GHRH analogs can stimulate the GH axis.

Related DAC biomarker studies

2006 CJC-1295 DAC studies raised GH and IGF-1 in healthy adults, but measured biomarkers rather than no-DAC outcomes.

No-DAC outcome trials

None found for marketed no-DAC products, and the registered DAC visceral-obesity trial has no posted efficacy result.

Market reality

Gray-market Mod GRF vials, FDA naming and safety concerns for CJC-1295-related substances, and no approved no-DAC product.

Study / evidence area	Population	Design	Product context	Main outcome	Limitations	Weight
FDA review of CJC-1295-related substances FDA	People potentially exposed to compounded or marketed CJC-1295-related products	Regulatory review and compounding-policy analysis	CJC-1295-related bulk substances, including DAC and non-DAC categories	FDA materials described inconsistent naming, different active moieties, limited clinical data, product-characterization concerns, and open safety questions.	The review is not a direct no-DAC efficacy trial, but it is highly relevant to identity, safety, and product-quality claims.	moderate
Related CJC-1295 DAC healthy-adult studies PMID 16352683 PMID 17018654 FDA	Healthy adults	Human pharmacology studies	Related DAC CJC-1295 evidence	Subcutaneous DAC exposure raised GH and IGF-1 biomarkers over days in small healthy-adult studies.	DAC evidence belongs to DAC products, and biomarker changes do not answer body-composition, sleep, recovery, or anti-aging claims for no-DAC products.	weak to moderate for related DAC biomarkers; weak for no-DAC claims
Older GHRH-fragment and D-Ala2-GHRH analog studies PMID 6236914 PMID 2866496	Human endocrine research participants in older GHRH studies	Historical human pharmacology context	GHRH-fragment and analog research, not modern no-DAC commercial vials	These papers help explain why modified GHRH analogs were studied for GH-axis effects.	They do not answer modern CJC-1295 no-DAC product equivalence, dosing, long-term safety, or clinical benefit.	weak for no-DAC outcomes; helpful for mechanism
Clinic, vendor, Reddit, and forum discussion FDA	People discussing or marketing non-approved peptide use	Anecdotal and market observation	Clinic, vendor, gray-market, forum, and Reddit sources	These sources commonly discuss fat loss, lean mass, sleep, recovery, anti-aging, pulse timing, and CJC/ipamorelin stacks.	They usually lack verified product identity, controlled outcomes, consistent dosing, medical monitoring, and reliable adverse-event capture.	anecdotal

Cautions

Safety and unknowns

Direct long-term safety data for modern marketed no-DAC products are not well characterized.
FDA materials raise peptide-specific concerns including immunogenicity, aggregation, impurities, characterization problems, and limited clinical data.
Related DAC human studies reported injection-site reactions and systemic symptoms in FDA summaries; those findings cannot define the no-DAC risk rate, but they make casual "well tolerated" claims unreliable.
GH and IGF-1 excess biology can matter for glucose handling, fluid retention, nerve symptoms, neoplasia concerns, and pituitary-axis effects, especially when exposure is repeated or poorly monitored.
Clinic, forum, and Reddit reports can miss adverse events because users may not verify the product, report labs, track IGF-1, or follow medical endpoints.
Blends with ipamorelin or other secretagogues make attribution harder because the GHRH pathway is being combined with ghrelin-receptor signaling.

Product quality

A vial label is only a starting point

The largest product-quality issue is identity: CJC-1295, CJC-1295 DAC, CJC-1295 no DAC, Modified GRF, acetate, free base, and blends can be confused in marketing.

FDA materials describe concerns about characterization, impurities, aggregates, bioburden, endotoxin, formulation, and storage for CJC-1295-related substances.

A vendor purity percentage or compact COA leaves the main injection questions open: identity, concentration, sterility, endotoxin, aggregation, storage, and degradation.

Identity and DAC status

DAC status changes exposure time and determines whether related human pharmacology sources are even talking about the same kind of molecule.

Salt form and concentration

Free base, acetate, and other forms can complicate label interpretation, assay comparison, and dose math.

Sterility and endotoxin

Subcutaneous use makes microbial contamination and endotoxin risk separate from the headline purity number.

Impurities and aggregates

Peptide impurities and aggregates may affect immunogenicity and tolerability, and FDA materials specifically call out characterization problems.

Storage and degradation

Lyophilized and reconstituted peptide products can degrade with poor storage, shipping heat, repeated handling, or uncertain dating.

Mechanism

How it is proposed to work

CJC-1295 no DAC is discussed as a GHRH analog. In simple terms, it aims to press the body's own growth-hormone release pathway at the pituitary rather than supply growth hormone directly.

Native GHRH is short-lived, so analog design has historically focused on substitutions that resist rapid enzymatic breakdown while preserving GH-releasing activity.

DAC-linked CJC-1295 extends exposure through albumin-related chemistry; no-DAC lacks that extension, which is why market discussions often describe it as shorter acting.

GHRH analogs differ from ghrelin-mimetic secretagogues such as ipamorelin. Combining the two in a stack changes the biology and makes single-peptide claims harder to interpret.

Without the albumin-binding DAC group, CJC-1295 no DAC is the same tetrasubstituted GHRH(1-29) backbone, often called Mod GRF 1-29, with a half-life of about 30 minutes, which preserves a pulsatile GH pattern at the cost of multiple daily injections.

FAQ

Common questions

Is CJC-1295 no DAC the same evidence as CJC-1295 DAC?

No. FDA separates non-DAC and DAC CJC-1295 as different active moieties and says they are not the same, so DAC-specific human pharmacology and registry evidence does not back no-DAC CJC-1295 efficacy claims.

FDA

Does Modified GRF 1-29 have the same support as the DAC CJC-1295 studies?

No. Modified GRF and older GHRH-fragment literature can explain naming context, but direct modern no-DAC CJC-1295 efficacy evidence comparable to the DAC-specific studies remains unverified.

PMID 6236914 PMID 2866496 FDA

Is CJC-1295 no DAC FDA-approved?

No FDA-approved drug product is found. FDA states that none of the reviewed CJC-1295-related bulk substances are components of FDA-approved drugs.

FDA

Details

Technical details

CJC-1295 no DAC technical details

Class

Non-DAC GHRH analog label

Common aliases

Modified GRF 1-29, Mod GRF 1-29, CJC-1295 without DAC

Reported sequence

Tetrasubstituted GHRH(1-29)-NH2 backbone (Mod GRF 1-29), with substitutions at positions 2, 8, 15, and 27

Length

29 amino acids

Approval status

No FDA-approved no-DAC CJC-1295 drug product found

Product status

No approved consumer CJC-1295 product found

Common route in discussion